据报猫眼娱乐(01896.HK)入标竞投红馆及伊馆等康文署票务系统
据《苹果日报》引述消息人士报道,中国最大票务网站猫眼娱乐(01896.HK)已入标竞投康文署票务系统及营运服务标书,其他竞标者包括目前的营运商购票通(Cityline)、新世界(00017.HK)旗下快达票及本港初创公司iMusic。购票通已负责康文署票务系统及营运服务长达14年,合约将於2021年3月完结束,合约价值约为1.2亿元。根据标书,中标公司需要负责红磡体育馆及伊利沙伯体育馆等共28个场地的票务系统,并特定要求需要防止门票炒卖,并要求设立系统识别潜在的票务炒卖活动。据悉,各间入标公司或邀香港宽频(01310.HK)及电盈(00008.HK)在技术层面上合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.